- Home
- PMVP vs BEAT Comparison
PMVP vs BEAT Comparison
Compare PMVP & BEAT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PMVP
- BEAT
- Stock Information
- Founded
- PMVP 2013
- BEAT 2015
- Country
- PMVP United States
- BEAT United States
- Employees
- PMVP N/A
- BEAT N/A
- Industry
- PMVP Medicinal Chemicals and Botanical Products
- BEAT Retail: Computer Software & Peripheral Equipment
- Sector
- PMVP Health Care
- BEAT Technology
- Exchange
- PMVP Nasdaq
- BEAT Nasdaq
- Market Cap
- PMVP 55.1M
- BEAT 51.1M
- IPO Year
- PMVP 2020
- BEAT 2021
- Fundamental
- Price
- PMVP $1.31
- BEAT $1.29
- Analyst Decision
- PMVP Strong Buy
- BEAT Buy
- Analyst Count
- PMVP 1
- BEAT 1
- Target Price
- PMVP $5.00
- BEAT $8.00
- AVG Volume (30 Days)
- PMVP 265.0K
- BEAT 158.9K
- Earning Date
- PMVP 08-07-2025
- BEAT 08-13-2025
- Dividend Yield
- PMVP N/A
- BEAT N/A
- EPS Growth
- PMVP N/A
- BEAT N/A
- EPS
- PMVP N/A
- BEAT N/A
- Revenue
- PMVP N/A
- BEAT N/A
- Revenue This Year
- PMVP N/A
- BEAT N/A
- Revenue Next Year
- PMVP N/A
- BEAT N/A
- P/E Ratio
- PMVP N/A
- BEAT N/A
- Revenue Growth
- PMVP N/A
- BEAT N/A
- 52 Week Low
- PMVP $0.81
- BEAT $1.17
- 52 Week High
- PMVP $1.82
- BEAT $3.48
- Technical
- Relative Strength Index (RSI)
- PMVP 68.35
- BEAT 36.52
- Support Level
- PMVP $0.96
- BEAT $1.17
- Resistance Level
- PMVP $1.36
- BEAT $1.37
- Average True Range (ATR)
- PMVP 0.09
- BEAT 0.10
- MACD
- PMVP 0.02
- BEAT -0.01
- Stochastic Oscillator
- PMVP 79.80
- BEAT 26.67
About PMVP PMV Pharmaceuticals Inc.
PMV Pharmaceuticals Inc is a precision oncology company. The company is engaged in the research and development of small molecule, tumor-agnostic therapies targeting p53 mutations, which can eliminate cancer cells. Its pipeline rezatapopt PYNNACLE, rezatapopt and azacitidine, rezatapopt (PC14586), and PMV-586-101.
About BEAT Heartbeam Inc.
HeartBeam Inc is a medical technology company primarily focusing on developing and commercializing higher resolution ambulatory Electrocardiogram ("ECG") solutions that enable the detection and monitoring of cardiac disease outside a healthcare facility setting. The Company's ability to develop higher-resolution ECG solutions is achieved through the development of the Company's proprietary and patented Vector Electrocardiography ("VECG") technology platform. The Company has validated this technology and is seeking U.S. Food and Drug Administration ("FDA") clearance for its initial telehealth products.